Myo-inositol Effects on Induction of Ovulation in Women with Polycystic Ovary Syndrome

Background: A long-term, multi-systemic metabolic-endocrine condition known as polycystic ovarian syndrome (PCOS) raises the risk of female neoplasms and has an impact on reproductive health. Aim and objectives: In order to assess the impact of Myo-inositol (MI) supplementation on ovulatory function and fertility in a woman with polycystic ovarian syndrome. Patients and methods: This prospective observational cohort investigation was conducted on 200 patients with PCOS at Al-Hussein University Hospital. Results: Hirsutism was found in 42.5%, acne was found in 50.5%, and alopecia was found in 14.5%. The median number of follicles was 2.32 ± 1.32, and the median largest follicle diameter was 15.9 ± 0.271 mm. There was a substantial decrease in serum androstenedione, total testosterone, and free testosterone post myo-inositol. Moreover, there is a substantial rise in serum progesterone post myo-inositol. Sixty-six 66% of the patients showed ovulation with a mean ovulation time of 14.74 ± 1.32. Moreover, 12% of the patients showed menstrual bleeding abnormality, and 78% of the patients showed restoration of spontaneous ovarian activity. While 51% of the patients were positive for pregnancy. Conclusion: For PCOS women, myo-inositol treatment is a safe, efficient method of ovulation induction and conception. They have resulted in considerable restoration of spontaneous ovarian activity and improvement in pregnancy rate.